BriaCell Therapeutics Corp. is a biotechnology company focused on developing immunotherapies for cancer treatment, with its lead candidate being Bria-IMT. While the company has a strong liquidity position indicated by a current ratio of 2.44 and no debt, it faces significant concerns with a negative return on equity and assets, suggesting operational inefficiencies. The recent price decline of 4.72% raises questions about market confidence, despite the promising nature of its immunotherapy pipeline. Overall, while the financial health score is decent, the negative profitability metrics warrant caution.
Loading financial metrics...
Company has $3.8M in cash but burned $8.0M last quarter. At this burn rate, only 0.5 quarters of runway remain without additional financing.
Company posted a loss of $-42.1M over the last year, representing Infinity% of revenue.
Operating cash flow has been negative for 3 consecutive quarters, burning $31.9M over the last year.
Debt-free balance sheet with a solid cash position, providing significant financial flexibility.
Strong liquidity position with current ratio of 2.4x.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Biotechnology companies of a similar size
Based on 2026-Q1 (October 31, 2025)